What are the typical presentation, diagnostic criteria, and recommended treatment for Goodpasture’s syndrome?

Goodpasture's Syndrome: Clinical Overview

Presentation and Pathophysiology

Goodpasture's syndrome is an autoimmune disease where anti-glomerular basement membrane (anti-GBM) antibodies attack the α3 chain of type IV collagen in both kidney and lung basement membranes, classically presenting as rapidly progressive glomerulonephritis with or without pulmonary hemorrhage. 1, 2

Classic Clinical Features

• Renal manifestations: Rapidly progressive glomerulonephritis with hematuria, proteinuria, and acute kidney injury progressing to dialysis dependence within days to weeks 3, 4
• Pulmonary manifestations: Hemoptysis, dyspnea, cough, and diffuse alveolar hemorrhage (present in approximately 60-90% when both organs involved) 1, 5
• Constitutional symptoms: Fatigue and malaise are common presenting features 4
• Demographics: Predominantly affects young men, though bimodal age distribution exists 2, 3

Triggering Factors

• Cigarette smoking is a major risk factor for pulmonary involvement 2, 4
• Hydrocarbon solvent exposure and cocaine abuse have been implicated 4
• Respiratory infections may precipitate disease onset 2
• Genetic susceptibility linked to HLA-DRB11501 and DRB11502 3

Diagnostic Approach

Laboratory Testing

• Serum anti-GBM antibodies: Positive in approximately 90% of cases (10% may be falsely negative) 1
• ANCA testing: Critical to perform simultaneously, as 20-35% are double-positive (anti-GBM + ANCA), which fundamentally changes long-term management 6, 3
• Kidney function: Serum creatinine level is the strongest predictor of renal recovery 7

Tissue Diagnosis

• Kidney biopsy findings: Necrotizing and crescentic glomerulonephritis with linear IgG staining on immunofluorescence along the glomerular basement membrane (pathognomonic finding) 1, 3
• Lung biopsy: Shows diffuse alveolar hemorrhage with linear IgG staining on alveolar basement membranes, though rarely needed 5

Critical Diagnostic Principle

Do not delay treatment waiting for biopsy results or antibody confirmation—if clinical suspicion is high, begin empirical therapy immediately with high-dose corticosteroids and plasmapheresis. 6, 8 The kidney biopsy can be performed after treatment initiation. 6

Treatment Protocol

Immediate Triple Therapy (Standard Regimen)

All patients with anti-GBM disease should receive cyclophosphamide, high-dose corticosteroids, and plasmapheresis without delay (Grade 1C recommendation). 6

Plasmapheresis

• Initiate daily plasmapheresis immediately (typically 60 mL/kg volume exchanges) 9, 8
• Continue daily until anti-GBM antibodies are undetectable on two consecutive tests, typically 14 days or 7-10 total treatments 6, 9, 8
• Use fresh frozen plasma as replacement fluid if active pulmonary hemorrhage is present or recent kidney biopsy performed; otherwise albumin is sufficient 8

Corticosteroids

• Pulse methylprednisolone 500-1000 mg IV daily for 3 days 9, 8
• Transition to oral prednisone with gradual taper over approximately 6 months 6, 9, 8

Cyclophosphamide

• Oral cyclophosphamide 2-3 mg/kg daily for 2-3 months (preferred over IV based on survival data) 8, 7
• Dose-adjust for reduced GFR and older age 8
• Rule out infection before initiating 8

Infection Prophylaxis

• Trimethoprim-sulfamethoxazole for Pneumocystis prophylaxis until cyclophosphamide is complete AND prednisone dose is <20 mg daily 9, 8

Critical Exception: When NOT to Treat

Withhold immunosuppression in patients who meet ALL three criteria: 6, 8

1. Dialysis-dependent at presentation
2. Kidney biopsy shows 100% crescents OR >50% global glomerulosclerosis
3. No pulmonary hemorrhage present

The rationale: renal recovery rate is only 8% in this population, and the risks of aggressive immunosuppression outweigh minimal benefit. 6

Absolute Override: Pulmonary Hemorrhage

Any patient with active pulmonary hemorrhage MUST receive full triple therapy regardless of renal status, dialysis dependence, or biopsy findings. 9, 8 Untreated pulmonary hemorrhage carries significant mortality risk, and lung disease responds well to aggressive treatment even when kidneys do not. 9

Prognostic Factors

Favorable Indicators for Renal Recovery

• Serum creatinine <500 μmol/L at presentation (strongest predictor) 8, 7
• Not requiring dialysis within 72 hours of presentation 8
• Early treatment initiation 6, 2

Poor Prognostic Indicators

• Dialysis-dependent at presentation: >90% remain on dialysis at 1 year, 35% mortality 8
• Serum creatinine >500 μmol/L 7
• 100% crescents on biopsy 6

Overall Survival

• One-year survival is approximately 87% with modern triple therapy 7
• Severe infection accounts for nearly half of deaths (7/16 in one large cohort) 7
• Age <60 years and adequate number of plasmapheresis sessions correlate with better survival 7

Maintenance Therapy and Long-Term Management

Isolated Anti-GBM Disease

No maintenance immunosuppression is required after completing the initial 6-month treatment course, as relapse rate is <5%. 6, 8 This distinguishes anti-GBM disease from ANCA-associated vasculitis. 6

Double-Positive Patients (Anti-GBM + ANCA)

Patients positive for both anti-GBM antibodies and ANCA require maintenance immunosuppression identical to ANCA-associated vasculitis protocols. 6, 8 These patients behave like AAV with similar relapse rates, not like isolated anti-GBM disease. 6, 8

Monitoring

• Monitor anti-GBM antibodies for at least 2 years, as rare relapses have been reported 8
• Antibodies typically become undetectable within weeks to months of treatment 6

Kidney Transplantation

Defer kidney transplantation until anti-GBM antibodies have been undetectable for a minimum of 6 months. 6, 8 Transplantation outcomes are generally favorable once antibodies clear, with low recurrence risk. 6

Common Pitfalls and How to Avoid Them

Pitfall 1: Delaying Treatment

Never wait for biopsy confirmation or antibody results before initiating therapy. 6, 8 Begin pulse methylprednisolone and plasmapheresis immediately when clinical suspicion is high based on rapidly progressive glomerulonephritis with or without pulmonary hemorrhage. 6, 9

Pitfall 2: Undertreating Severe Renal Impairment

Do not withhold treatment from patients with creatinine >500 μmol/L if they are not yet dialysis-dependent. 8 Some patients can still recover renal function even with severe impairment if treated early. 7

Pitfall 3: Failing to Treat Pulmonary Hemorrhage

Always treat pulmonary hemorrhage aggressively, regardless of renal involvement severity or dialysis status. 9, 8 The standard exception for dialysis-dependent patients does not apply when lungs are actively bleeding. 9

Pitfall 4: Forgetting ANCA Testing

Always test for ANCA simultaneously with anti-GBM antibodies. 3 Missing double-positive status leads to inappropriate omission of maintenance therapy and subsequent relapse. 6, 8

Pitfall 5: Confusing with Other Pulmonary-Renal Syndromes

Distinguish from ANCA-associated vasculitis, lupus nephritis, and other causes using linear IgG staining pattern on immunofluorescence (pathognomonic for anti-GBM disease). 1, 3 Do not confuse with hypersensitivity pneumonitis despite chemical exposure history—HP shows lymphocytic BAL and granulomas, not linear IgG staining. 1

Emerging Therapies

• Imlifidase (IgG-degrading enzyme): Phase 2 data shows rapid antibody decline within 6 hours and 67% dialysis-free survival at 6 months when combined with plasma exchange and corticosteroids 8
• Rituximab: Successfully used in case reports for patients with incomplete response to standard therapy 6
• Mycophenolate mofetil: Case reports describe successful substitution for cyclophosphamide 6